Instituto Tumori Giovanni Paolo II

Bari 70124

3 studies enrolling now · 4 studies all time

What they study most

Breast Neoplasm, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urinary Bladder Neoplasms

Studies at this site

• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer — Running, not enrolling